The University of Texas MD Anderson Cancer Center and Phoenix SENOLYTIX, Inc., today announced a global cross-licensing agreement to facilitate work that will further enhance the development of inducible switch technologies for use in cell and gene therapies.

Clinical trials show promising results in treating pancreatic and colorectal cancers

New treatment strategies improve outcomes for patients with kidney and testicular cancers

Novel research techniques enable advances in gene-drug interactions, breast cancer progression, and identifying pre-cancerous lesions

Biomarkers help predict risk for oral cancer metastasis

The addition of the hormone progesterone to gender-affirming hormone therapy leads to increased breast growth for transgender people following feminising hormone therapy. This is demonstrated by an Amsterdam UMC-led trial among 90 participants and these results are presented today at the European Professional Association for Transgender Health (EPATH) annual congress in Hamburg.

Blood pressure, body temperature, hormone levels: all these things aren’t static throughout the day. The same may be true for biological compounds found in breast milk, a new study has found. Using expressed breast milk, a team examined fluctuations of hormones like melatonin and cortisol, which impact babies’ circadian rhythm, and proteins that influence development and immunization. The team showed that certain compounds spiked at different times of the day. In a society where not every mother can stay with their baby around the clock, this information might allow for optimized feeding of expressed breast milk, the researchers said.